Key Insights

Highlights

Success Rate

78% trial completion

Published Results

28 trials with published results (19%)

Research Maturity

54 completed trials (37% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

10.3%

15 terminated out of 145 trials

Success Rate

78.3%

-8.2% vs benchmark

Late-Stage Pipeline

3%

5 trials in Phase 3/4

Results Transparency

52%

28 of 54 completed with results

Key Signals

28 with results78% success15 terminated

Data Visualizations

Phase Distribution

105Total
Not Applicable (43)
Early P 1 (1)
P 1 (36)
P 2 (20)
P 3 (3)
P 4 (2)

Trial Status

Completed54
Recruiting40
Terminated15
Unknown14
Active Not Recruiting10
Not Yet Recruiting5

Trial Success Rate

78.3%

Benchmark: 86.5%

Based on 54 completed trials

Clinical Trials (145)

Showing 20 of 20 trials
NCT06239194Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT00026884Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT06116253Not ApplicableActive Not RecruitingPrimary

Advanced Diffusion Imaging in Renal Cancer Patients

NCT01109394Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT07227415Phase 1Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT06760702Phase 2Terminated

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers

NCT05210933SuspendedPrimary

Study of Minimally-invasive Ablative Renal Therapies (SMART) Registry

NCT05969496Phase 2RecruitingPrimary

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

NCT02087852RecruitingPrimary

Kidney Cancer DNA Registry

NCT05888532Phase 1Recruiting

64Cu-GRIP B in Patients With Advanced Malignancies

NCT04987086Not ApplicableRecruitingPrimary

68Ga-PSMA PET in the Renal Cell Carcinoma

NCT05873686Phase 1Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

NCT07088536Recruiting

Occupational Situation and Return to Work of Urological Patients

NCT05225428Not ApplicableRecruiting

Video Education With Result Dependent dIsclosure

NCT00458536Phase 1CompletedPrimary

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

NCT07395037Recruiting

A Study of Ward Admissions for Haematuria

NCT03203473Phase 2Active Not RecruitingPrimary

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NCT06349668Phase 3Recruiting

Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery

NCT00582621Recruiting

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

NCT07299357RecruitingPrimary

Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial

Scroll to load more

Research Network

Activity Timeline